Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • NPPA fixes retail...

    NPPA fixes retail price of Emcure pharma's HIV drug

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-02-17T09:30:01+05:30  |  Updated On 13 Aug 2021 2:48 PM IST

    New Delhi: Through a recent notice, the drug price regulator National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of Emcure Pharmaceutical's formulation used to help control HIV infection.


    The Ministry of Chemicals and Fertilizers issued a recent notification in this regard. The retail price of the formulation of Abacavir +Dolutegravir + Lamivudine tablet has been fixed exclusive of goods and services tax(GST).


    Abacavir/dolutegravir/lamivudine is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of three drugs with different and complementary mechanisms of action: 600 mg abacavir (reverse transcriptase inhibitor), 50 mg dolutegravir (integrase inhibitor) and 300 mg lamivudine (nucleoside analog reverse transcriptase inhibitor).


    The drug was developed by ViiV Healthcare and approved by the Food and Drug Administration for use in the United States in August 2014.


    The formulation of each film-coated tablet contains Abacavir Sulphate IP eq. to Abacavir Abacavir 600 mg Dolutegravir Sodium eq. to Dolutegravir 50 mg Lamivudine IP 300 mg. The retail price of the formulation has been fixed as Rs 157.69 for the formulation that is made/sold by Emcure Pharmaceuticals


    The notice states



























    Sl.
    No
    Name of the
    Formulation / Brand Name
    StrengthUnitManufacturer &
    Marketing Company
    Retail
    Price
    (Rs.
    123456
    1Abacavir +
    Dolutegravir +
    Lamivudine tablet
    Each film coated tablet contains:
    Abacavir Sulphate IP eq. to Abacavir 600 mg
    Dolutegravir Sodium eq. to Dolutegravir 50 mg
    Lamivudine IP 300 mg
    TabletM/s Emcure
    Pharmaceuticals Ltd.
    157.96

    The notice further reads,




    • The manufacturer of above-mentioned formulation i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

    • The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.

    • The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

    • As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carried on business in a manner so as to be easily accessible to any person wishing to consult the same.

    • The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

    • In case the retail price of any of the aforesaid formulation is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

    • Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.


    Also Read: NPPA fixes the retail price of 29 drug formulations including BP, Cholesterol, pain medications; Details
    Alembic PharmaCadilaceiling priceDPCOformulationsGovernment of Indiagovt of indiaGSKindian govtindian pharma newsIndocolatest pharma newsLupinMinistry of Chemical and FertilizerNational Pharmaceutical Pricing AuthorityNPPANPPA price Fixationpharma newspharma news in indiaPharma Policy newsPharmacistspharmacy newspolicy newsprice fixationpricesSun Pharma

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok